|
|
|
|
| LEADER |
01874nam a2200229 u 4500 |
| 001 |
EB002001224 |
| 003 |
EBX01000000000000001164125 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a Optimal use of minimally invasive glaucoma surgery: Recommendations
|h Elektronische Ressource
|
| 246 |
3 |
1 |
|a Recommendations
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2019, 2019
|
| 300 |
|
|
|a 1 online resource
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH optimal use report
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK543013
|3 Volltext
|
| 082 |
0 |
|
|a 800
|
| 520 |
|
|
|a These recommendations were developed by the Health Technology Expert Review Panel (HTERP) based on evidence reviewed in a CADTH Health Technology Assessment (HTA) report. The HTA included a review of the clinical effectiveness and safety, cost-effectiveness, patients' and caregivers' perspectives and experiences, ethical issues, and implementation issues regarding minimally invasive glaucoma surgery (MIGS) for the treatment of adults with glaucoma. The information retrieved and the HTERP deliberations aimed to address the policy questions: What is the optimal use, including appropriate patient selection, of MIGS devices and procedures for adults with glaucoma? Should MIGS devices and procedures be funded by the public health care system? The target population for these recommendations is patients with glaucoma who are deemed eligible for MIGS by their care provider. The target users of these recommendations are Canadian health care decision-makers, those in provincial and territorial ministries of health, and glaucoma researchers
|